Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.
about
Current trends in management of hepatitis B virus reactivation in the biologic therapy eraKASL clinical practice guidelines: management of chronic hepatitis BHepatitis B and Hepatitis C Reactivation in the Biologic EraHepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel diseaseHepatitis B virus reactivation with rituximab-containing regimenOccult hepatitis B virus infectionClinical impact of occult hepatitis B virus infection in immunosuppressed patientsAcute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis BDiagnosis of hepatitis BTreatment of rheumatic diseases and hepatitis B virus coinfectionReactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinomaHospital cluster of HBV infection: molecular evidence of patient-to-patient transmission through lancing device.Prevention of hepatitis B virus reactivation under rituximab therapy.Bortezomib induced hepatitis B reactivation.Effect of Antiviral Prophylaxis Strategy for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients with Hepatitis B Virus Infection: A Retrospective Cohort Study.Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities.Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.Recent advances in managing hepatitis B.Chronic hepatitis B: integrating long-term treatment data and strategies to improve outcomes in clinical practiceHepatitis B virus management to prevent reactivation after chemotherapy: a review.Chemotherapy-related reactivation of hepatitis B infection: updates in 2013.2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.Clinical and virological responses to clevudine therapy of hepatocelluar carcinoma patients with chronic hepatitis B.Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reportsCurrent hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists.Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center.Risk factors for hepatitis B virus reactivation after conformal radiotherapy in patients with hepatocellular carcinoma.The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder systemPoor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening.Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B.Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure.Hepatitis B reactivation and rituximab in the oncology practice.When treating cancer, please don't forget hepatitis B.Consensus statement on the use of rituximab in patients with rheumatoid arthritisA Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic ChemotherapyAssociation between hepatitis B virus infection and risk of multiple myeloma: a systematic review and meta-analysis.The Impact of Chemotherapy on Hepatitis B Antibody Titer in Patients with Hematological Malignancies.Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma.Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization.
P2860
Q24634879-7084892C-02AF-4EB7-B9C8-645F5E892A14Q26752475-B8787458-E9C1-42FF-AC06-7E5C601284A1Q26781993-95F30A33-D305-424D-970F-DC2AD5E47053Q26827444-092239BB-ED45-416E-8E34-7A0EFD4F272BQ26830484-AB7D5F2F-9E59-4A86-BCB3-3DD4625C7F18Q27004224-6ADD9651-E7EA-499E-9E4B-BA98236A3319Q27006996-FFE62926-0DCA-4E2E-AA75-C38EAC869849Q27022622-D482F58D-B638-4076-81AC-4B50C437EE6AQ28071817-F4F1D677-ED3E-4945-A5EA-6AF98B2AE39EQ28084305-68BB25B6-B574-4100-8D69-94DEEAD15BC4Q28546530-3E822742-BA60-4554-9494-E8912D1FDF0EQ31050747-60B961FB-FA48-4BB2-993E-85F2C40D62C3Q33390799-1342C099-46BB-475A-9557-F25FA08D0C15Q33615071-CCD934E9-2CAD-42E0-89FB-9E8E05E2E380Q33619636-188582D4-63C6-44EF-8B55-DAEA84C53A17Q33735212-4E686244-0E8A-4B02-BEE0-B36DB0135D0DQ33746887-A3D7A678-CEA8-46E6-BC12-5EA86903AA47Q33825391-2090342F-91B1-4498-B9B9-3F61B10F2619Q34167574-FCAC974C-03B7-4A6A-A650-E824A5F3D102Q34256062-0035B6DA-4B63-4343-A37C-AADF1388ED54Q34397738-967CBA33-6FE3-4375-AD8B-50B95A76E819Q34404991-D9627432-D6B6-4696-9E8A-07E4F94C2AF2Q34500921-74FCA150-AE0C-4826-96DB-EFB01EE57697Q34725898-46A05024-EA03-4FC2-9A3F-DD48E4AB289AQ34854165-F07022FB-482B-4509-BE4F-68CB1479037FQ34974883-B91C4AC3-C191-4236-A92C-318626513E3EQ35037621-EC7FCB06-96C4-4EFA-A67A-23A5C73B2883Q35051831-BD852FDE-8E90-4963-A068-8B3E63CE0514Q35057889-92932C46-423A-4A8A-A4F4-1ECA79DA589EQ35429416-B43A3B4D-9EB8-4B8E-94A5-5C737C2C0508Q35567341-BA343A51-01B8-4337-99D7-0EDC47508068Q35567748-6DA0F715-718D-46CA-B9F6-1C0F83C56C17Q35583718-30133BC2-9A62-4F82-849F-E7F16306554EQ35584210-AD51B27A-80CD-4F9D-B417-050723E3F4A4Q35638676-100CE50A-4FA1-4F62-AEE4-78A8C0D7783CQ35677319-AD4EF42F-F7B3-4E1E-B154-F56516298D88Q35867759-E361C9DE-3238-4979-8807-1E7A393234ABQ36038914-ED8F875F-1B41-48F8-BACD-3FE574D76325Q36074220-9CDE22FD-ED20-4BF3-9EB6-F16999103D45Q36121202-0B142F5E-71D7-424A-B2BC-B0791C864578
P2860
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Diagnosis, prevention and mana ...... ion during anticancer therapy.
@ast
Diagnosis, prevention and mana ...... ion during anticancer therapy.
@en
type
label
Diagnosis, prevention and mana ...... ion during anticancer therapy.
@ast
Diagnosis, prevention and mana ...... ion during anticancer therapy.
@en
prefLabel
Diagnosis, prevention and mana ...... ion during anticancer therapy.
@ast
Diagnosis, prevention and mana ...... ion during anticancer therapy.
@en
P2860
P356
P1433
P1476
Diagnosis, prevention and mana ...... ion during anticancer therapy.
@en
P2093
Philip J Johnson
Winnie Yeo
P2860
P304
P356
10.1002/HEP.21051
P407
P577
2006-02-01T00:00:00Z